Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2021 Jan. 1 [cited 2025 Apr. 19];5(1):s19. Available from: https://skin.dermsquared.com/skin/article/view/1172